LAUSR

Long noncoding RNA (lncRNA) AGAP2 antisense RNA 1 (AGAP2‐AS1) has been suggested to function as an oncogenic lncRNA in lung cancer, breast cancer, and anaplastic glioma. However, the expression pattern and molecular mechanism of AGAP2‐AS1 in glioblastoma multiforme (GBM) remains unknown. The purpose of this study is to present more evidence about the clinical and biological function of AGAP2‐AS1 in GBM. In our results, we found AGAP2‐AS1 expression was increased in GBM compared with adjacent normal brain tissues or low‐grade glioma tissues, and there was no significantly different between low‐grade glioma tissues and normal tissues. Kaplan‐Meier survival analysis indicated patients with GBM having high‐expression of AGAP2‐AS1 had shorter overall survival time than those with low expression of AGAP2‐AS1. The loss‐of‐function studies showed that downregulation of AGAP2‐AS1 depressed cell proliferation, migration, and invasion, and promoted cell apoptosis in GBM. In summary, AGAP2‐AS1 is a prognostic biomarker for patients with GBM, and functions as an oncogenic lncRNA to modulate GBM cell proliferation, apoptosis, migration, and invasion, which suggests that AGAP2‐AS1 is potential therapeutic target for GBM.